House Bill 925, the Consumers in Crisis Protection Act, creates a new Article 94 in Chapter 58 of the North Carolina General Statutes to regulate consumer legal funding transactions. These transactions are defined as nonrecourse arrangements in which a consumer sells a contingent interest in future settlement or judgment proceeds from a legal claim in exchange for funds to cover personal or household needs. The bill expressly states that compliant consumer legal funding transactions are not loans and are not governed by general loan or investment-contract laws.
The bill establishes a licensing and oversight framework under the Commissioner of Insurance. Consumer legal funding companies must register, pay a fee, submit financial and background information, maintain proof of financial stability, and file contract templates and disclosures. The measure also sets contract requirements such as plain-language terms, attorney acknowledgment, a rescission right, disclosure of charges and repayment limits, and a prohibition on charging beyond 36 months. It limits certain charges, bars funding companies from influencing litigation decisions, and prohibits referral fees, legal advice, misleading advertising, and other practices. The bill also includes attorney-related restrictions, discovery and disclosure rules, examination authority for the Department of Insurance, civil penalties, restitution, and enforcement powers.
The bill’s impact on state law is to create a comprehensive regulatory regime for a relatively new form of litigation-related financing, while also declaring that compliant transactions are not loans and supersede conflicting laws for this purpose. It would affect consumer legal funding companies, consumers involved in civil claims, attorneys representing those consumers, and the Department of Insurance. It also addresses lien priority, nonrecourse repayment limits, confidentiality and discovery issues, and the treatment of transactions involving multiple funding agreements or foreign adversary funding sources.
The general sentiment reflected in the available record appears neutral to favorable, but there is limited discussion or voting history available. The bill was reported as a committee substitute favorable, suggesting at least some legislative support for moving the measure forward in its revised form. Because no committee transcript or recorded votes were provided, there is no evidence in the record of organized opposition or floor debate.
The main points of contention likely concern consumer protection versus access to litigation funding. The bill imposes substantial disclosure, registration, and conduct restrictions, which may be viewed by supporters as necessary safeguards against predatory practices, while critics could view them as burdensome or as limiting a consumer’s ability to obtain emergency funds tied to a legal claim. Additional potentially sensitive issues include attorney involvement, lien priority, the cap on charges, the prohibition on foreign adversary funding, and the rule that these transactions are not treated as loans.
The bill adds a new regulatory article to Chapter 58 governing consumer legal funding companies and consumer legal funding contracts. It requires registration with the Commissioner of Insurance, mandates disclosures and contract terms, limits charges and repayment obligations, sets attorney and company conduct rules, and authorizes examinations, rulemaking, penalties, restitution, and cease-and-desist enforcement. It also provides that compliant transactions are not loans and are not subject to conflicting loan or investment-contract laws, thereby reshaping how these arrangements are treated under North Carolina law.
The available legislative record suggests a generally favorable or at least noncontroversial posture toward the bill, as indicated by the committee substitute favorable designation. However, there is no transcript or vote history to show detailed debate, so the overall sentiment can only be described as limited and cautiously supportive rather than strongly documented. The absence of recorded opposition in the provided materials points to no visible public controversy in the record supplied.
Likely areas of contention include whether consumer legal funding should be treated as a protected financial product or as a high-cost, litigation-adjacent practice requiring strict oversight. Supporters would likely emphasize consumer protections such as rescission rights, disclosure requirements, charge limits, and bans on attorney influence or referral payments. Potential critics may focus on the administrative burden of registration, the restrictions on contract terms and charges, the attorney attestation requirements, and the bill’s broad regulatory reach over a financing product used by injured or financially distressed claimants. The foreign adversary funding ban and the rules on lien priority and discovery could also draw scrutiny from industry participants and litigation stakeholders.